2023
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY
Idalsoaga F, Díaz L, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Grawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, P N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY. Annals Of Hepatology 2023, 28: 101035. DOI: 10.1016/j.aohep.2023.101035.Peer-Reviewed Original ResearchCox regressionSevere AHCohort studyHigh mortalityAlcohol‐Associated HepatitisRetrospective cohort studyKaplan-Meier curvesShort-term mortalityGlobal cohort studyLille modelMultivariable analyzesCorticosteroid treatmentMELD scoreAH patientsSevere entitySerum bilirubinClinical variablesBetter prognosticationWorldwide cohortSevere diseasePatientsDay 7Predicting ResponseDay 4Corticosteroids
2022
Preventing Further Decompensation: Consensus Statements of Panel 7
Garcia-Tsao G, Reiberger T, Bureau C, D’Amico G, La Mura V, Piano S, Tandon P, Turco L. Preventing Further Decompensation: Consensus Statements of Panel 7. 2022, 579-583. DOI: 10.1007/978-3-031-08552-9_51.Peer-Reviewed Original ResearchConcept of Further Decompensation and Recompensation
D’Amico G, Garcia-Tsao G. Concept of Further Decompensation and Recompensation. 2022, 523-535. DOI: 10.1007/978-3-031-08552-9_47.Peer-Reviewed Original Research
2021
Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort
Bajaj JS, Garcia‐Tsao G, Wong F, Biggins SW, Kamath PS, McGeorge S, Chew M, Pearson M, Shaw J, Kalluri A, Fagan A, Olofson A, Moini M, de la Rosa Rodriguez R, Reddy KR. Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort. Liver Transplantation 2021, 27: 1343-1347. PMID: 33427401, PMCID: PMC8014819, DOI: 10.1002/lt.25981.Peer-Reviewed Original Research
2020
Intestinal Virome in Patients With Alcoholic Hepatitis
Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, Schwanemann LK, Ventura‐Cots M, Bataller R, Bosques‐Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia‐Tsao G, Kisseleva T, Brenner DA, Tu XM, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology 2020, 72: 2182-2196. PMID: 32654263, PMCID: PMC8159727, DOI: 10.1002/hep.31459.Peer-Reviewed Original ResearchConceptsAlcohol-associated liver diseaseAlcohol use disorderAlcoholic hepatitisDisease severityEnd-stage liver disease (MELD) scoreFecal samplesLiver Disease scoreMulticenter observational studyVirus-like particlesHigher median ModelIntestinal viromeLiver diseaseSevere manifestationsAntibiotic treatmentObservational studyDisease scoreUse disordersPatientsHigh mortalityViral diversityGut bacteriaViral microbiomeMortalitySeverityHepatitis
2018
Ascites
Garcia‐Tsao G. Ascites. 2018, 127-150. DOI: 10.1002/9781119237662.ch9.Peer-Reviewed Educational MaterialsLarge-volume paracentesesHepatorenal syndromeRefractory ascitesCirrhotic ascitesCommon decompensating eventMassive hepatic metastasesPlasma renin activitySecond-line treatmentFormation of ascitesDevelopment of ascitesCost-effective treatmentSinusoidal hypertensionCardiac indexRenin activityVasodilatory stateHepatic metastasesMalignant ascitesAscites formationCommon precipitantsAscitesHigh mortalityBacterial infectionsHyponatremiaMain predictorsPatients
2017
Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation
Bhutta A, Garcia‐Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Alimentary Pharmacology & Therapeutics 2017, 47: 78-85. PMID: 28994122, PMCID: PMC6016372, DOI: 10.1111/apt.14366.Peer-Reviewed Original ResearchConceptsMean arterial pressureBeta-blocker useLower mean arterial pressureBeta-blocker discontinuationRefractory ascitesHigh mortalityLower white blood cell countBeneficial anti-inflammatory effectsWhite blood cell countAcute kidney injuryAnti-inflammatory effectsTime of discontinuationBlood cell countEffect of BBBB discontinuationKidney injuryChart reviewHospital dischargeArterial pressureDiscontinuationAscitesCirrhosisPatientsCell countMortalityChapter 36 Ascites
Garcia-Tsao G. Chapter 36 Ascites. 2017, 475-484. DOI: 10.1016/b978-0-12-804274-8.00036-9.Peer-Reviewed Educational MaterialsRefractory ascitesCommon decompensating eventNew-onset ascitesSodium-retaining systemsFirst-line therapyDevelopment of ascitesCause of deathPortal hypertensionRenal failureSodium retentionPathophysiological mechanismsOvert infectionAscitesPathogenic cascadeHigh mortalityVasodilatationEarly placementPatientsCirrhosisDeathHypertensionTherapyInfectionMortality
2011
Intensive care of the patient with cirrhosis
Olson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia‐Tsao G, Kamath PS. Intensive care of the patient with cirrhosis. Hepatology 2011, 54: 1864-1872. PMID: 21898477, DOI: 10.1002/hep.24622.Peer-Reviewed Original ResearchConceptsMultiple organ failureIntensive care unitCare unitOrgan failureLiver functionSignificant survival benefitPresence of infectionFurther deteriorationQuality of lifeNumber of organsLiver support systemsAlcoholic hepatitisLiver transplantationVariceal hemorrhageAcute deteriorationCommon organLiver dysfunctionSurvival benefitViral hepatitisIll patientsIntensive careCritical carePatientsHigh mortalityTeam approach
1995
Variceal Hemorrhage
Navarro V, Garcia-Tsao G. Variceal Hemorrhage. Critical Care Clinics 1995, 11: 391-414. PMID: 7788538, DOI: 10.1016/s0749-0704(18)30073-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsVariceal bleedingVariceal hemorrhageFirst variceal bleedingHigh recurrence ratePortal hypertensionBalloon tamponadePharmacologic therapyPortal pressureShunt surgeryActive hemorrhageRecurrence rateBlood flowTherapeutic avenuesHigh mortalityHemorrhageBleedingPreventionHypertensionTamponadeSclerotherapyComplicationsSurgeryRelative effectivenessTherapyMortality